Carcinoma in situ outcomes in National surgical Adjuvant breast and Bowel Project breast cancer chemoprevention trials

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 181-186

  Vogel, Victor G ^a,b   Costantino, Joseph P ^a,c   Lawrence, Wickerham D ^a,d   Mccaskill stevens, Worta ^e   Clarfeld, Richard B ^f   Grant, Michael D ^g   Wolmark, Norman ^a,d  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Division of Breast Surgery   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; HYPERPLASIA; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ENDOMETRIUM TUMOR; INCIDENCE; LUNG CARCINOMA; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); PAGET NIPPLE DISEASE; REVIEW; STATISTICS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; INCIDENCE; MULTICENTER STUDIES AS TOPIC; PULMONARY EMBOLISM; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79952199257     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq041     Document Type: Article

References (16)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst. 1998;90(8):1371-1388.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst. 2005;97(22):1652-1662.
3. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(29):1879-1886.
4. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-1846.
5. Cauley JA, Lucas FL, Kuller LH, et al. Study of Osteoporotic Fractures Research Group. Bone mineral density and risk of breast cancer in older women: the Study of Osteoporotic Fractures. JAMA. 1996;276(17):1404-1408.
6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189-2197.
7. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287(2):216-220.
8. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65(2):125-134.
9. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol. 2001;19(12):3111-3116.
10. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
11. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prevent Res. 2010;3(6):696-706.
12. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751-1761.
13. Cirpan T, Akercan F, Itil M, et al. Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal women? Eur J Gynaecol Oncol. 2006;27(2):177-178.
14. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1696-1701.
15. Konez O, Goyal M, Reaven RE. Can tamoxifen cause a significant mammographic density change in breast parenchyma? Clin Imaging. 2001;25(5):303-308.
16. Chow CK, Venzon D, Jones EC, et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev. 2000;9(9):917-921.